Drug profile · INN
volanesorsen
WAYLIVRA
volanesorsen (WAYLIVRA) is a apolipoprotein c-iii mrna 3'utr antisense inhibitor.
EMA: approved Cardiovascular system (C10) C10AX18
Patents linked 0
Pipeline programs 4
News articles 0
Drug details — volanesorsen
- Class
- Cardiovascular system (C10)
- Route
- —
- Patents
- 0
- Programs
- 4
- Data quality
- 0.83
Quick answer
volanesorsen (WAYLIVRA) is a apolipoprotein c-iii mrna 3'utr antisense inhibitor.
Key facts
INN volanesorsen
Brand WAYLIVRA
Mechanism Apolipoprotein C-III mRNA 3'UTR antisense inhibitor
Therapeutic class Cardiovascular system (C10)
ATC code C10AX18
Mechanism of action
Apolipoprotein C-III mRNA 3'UTR antisense inhibitor
Approval history
| Authority | Status | Date |
|---|---|---|
| EMA | approved | — |
Pipeline programs
Related & competitor drugs
Frequently asked questions
What is volanesorsen?
volanesorsen (WAYLIVRA) is a apolipoprotein c-iii mrna 3'utr antisense inhibitor.
What is the brand name for volanesorsen?
WAYLIVRA is a marketed brand name for volanesorsen. Check FDA Drugs@FDA for the current US label holder and prescribing information.